<DOC>
	<DOCNO>NCT01076556</DOCNO>
	<brief_summary>This phase I trial study side effect best dose alvocidib give together cyclophosphamide rituximab treat patient high risk B-cell chronic lymphocytic leukemia small lymphocytic lymphoma . Drugs use chemotherapy , cyclophosphamide , work different way stop growth cancer cell , either kill cell stop dividing . Alvocidib may stop growth cancer cell block enzymes need cell growth . Monoclonal antibody , rituximab , also block cancer growth different way . Some block ability cancer cell grow spread . Other find cancer cell help kill carry cancer-killing substance . Giving cyclophosphamide , alvocidib , rituximab together may kill cancer cell .</brief_summary>
	<brief_title>Cyclophosphamide , Alvocidib , Rituximab Treating Patients With High Risk B-Cell Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine dose-limiting toxicity maximum-tolerated dose treatment cyclophosphamide , alvocidib , rituximab patient high-risk B-cell chronic lymphocytic leukemia small lymphocytic lymphoma . II . To determine feasibility administer regimen outpatient regimen patient . SECONDARY OBJECTIVES : I . To determine complete response rate , partial response rate , minimal-residual disease-negative response rate patient treat regimen . II . To determine pharmacokinetics alvocidib dexamethasone part regimen . III . To determine immunologic effect regimen measure serial T-cell NK-cell number , T-cell function , immunoglobulin level . OUTLINE : This dose-escalation study alvocidib . Patients receive rituximab IV 4 hour day 1 ( day 1-3 course 1 ) , cyclophosphamide IV 30-60 minute day 1-3 , alvocidib IV 4.5 hour day 1 8 ( day 8 course 1 ) . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . Blood sample collect periodically pharmacokinetic pharmacodynamic study . After completion study treatment , patient follow 5 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Leukemia , Prolymphocytic</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Alvocidib</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically confirm chronic lymphocytic leukemia ( CLL ) Bcell prolymphocytic leukemia* ( PLL ) arise CLL Patients must document Bcell lymphocytosis &gt; 5 x 10^9/L point since initial diagnosis CLL Patients must Bcells coexpress CD5 CD19 CD20 Patients dim sIg CD23 expression leukemia cell examine cyclin D1 overexpression ( 11 ; 14 ) rule mantle cell lymphoma To consider high risk , patient must meet following criterion : At least 1 follow : 17p deletion 11q deletion Unmutated IgV_H ( ≥ 98 % homology ) Age &gt; 70 year B_2M &gt; 4 AND least 1 follow : Progressive mark splenomegaly and/or lymphadenopathy Anemia ( hemoglobin &lt; 11 g/dL ) thrombocytopenia ( platelet &lt; 100,000/mm^3 ) Weight loss exceed 10 % body weight precede 6 month NCI grade 2 3 fatigue Fevers &gt; 100.5° F night sweat &gt; 2 week without evidence infection Progressive lymphocytosis , increase exceed 50 % 2month period double time &lt; 6 month No concurrent hormone , chemotherapy , radiotherapy except steroid new adrenal failure hormone nondiseaserelated condition ( e.g. , insulin diabetes ) No requirement chronic corticosteroid ECOG performance status 02 Creatinine ≤ 2.0 mg/dL Bilirubin ≤ 1.5 time normal unless due Gilbert disease , hemolysis , disease infiltration liver AST ≤ 2 time normal unless due hemolysis disease infiltration liver Negative pregnancy test Not pregnant nursing Fertile patient must use effective contraception No secondary malignancy limit survival &lt; 2 year No uncontrolled concurrent illness include , limited , follow : Ongoing active infection Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia Psychiatric illness social situation would limit compliance study requirement No uncompensated HIV without adequate CD4 ( &gt; 200/mm^3 ) require HIV medication No active hepatitis B infection No know G6PD deficiency No history allergic reaction attribute compound similar chemical biologic composition alvocidib , cyclophosphamide , rituximab , agent use study No prior alvocidib No prior purine analog therapy No 1 prior treatment biologic alkylating agent No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>